IL215584A - Use of 5- (fluoromethyl) piperidine-3,4-diol, 5- (chloromethyl) piperidine-3,4-diol for the preparation of a drug for the prevention and / or treatment of degenerative diseases of the central nervous system - Google Patents

Use of 5- (fluoromethyl) piperidine-3,4-diol, 5- (chloromethyl) piperidine-3,4-diol for the preparation of a drug for the prevention and / or treatment of degenerative diseases of the central nervous system

Info

Publication number
IL215584A
IL215584A IL215584A IL21558411A IL215584A IL 215584 A IL215584 A IL 215584A IL 215584 A IL215584 A IL 215584A IL 21558411 A IL21558411 A IL 21558411A IL 215584 A IL215584 A IL 215584A
Authority
IL
Israel
Prior art keywords
piperidine
diol
fluoromethyl
chloromethyl
medicament
Prior art date
Application number
IL215584A
Other languages
English (en)
Hebrew (he)
Other versions
IL215584A0 (en
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of IL215584A0 publication Critical patent/IL215584A0/en
Publication of IL215584A publication Critical patent/IL215584A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL215584A 2009-04-09 2011-10-06 Use of 5- (fluoromethyl) piperidine-3,4-diol, 5- (chloromethyl) piperidine-3,4-diol for the preparation of a drug for the prevention and / or treatment of degenerative diseases of the central nervous system IL215584A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16810109P 2009-04-09 2009-04-09
PCT/US2010/030470 WO2010118282A1 (en) 2009-04-09 2010-04-09 Methods for preventing and/or treating degenerative disorders of the central nervous system

Publications (2)

Publication Number Publication Date
IL215584A0 IL215584A0 (en) 2011-12-29
IL215584A true IL215584A (en) 2016-11-30

Family

ID=42934882

Family Applications (1)

Application Number Title Priority Date Filing Date
IL215584A IL215584A (en) 2009-04-09 2011-10-06 Use of 5- (fluoromethyl) piperidine-3,4-diol, 5- (chloromethyl) piperidine-3,4-diol for the preparation of a drug for the prevention and / or treatment of degenerative diseases of the central nervous system

Country Status (11)

Country Link
US (1) US8304429B2 (enExample)
EP (1) EP2416655B1 (enExample)
JP (1) JP5634498B2 (enExample)
CN (1) CN102448306B (enExample)
AU (1) AU2010233187B2 (enExample)
BR (1) BRPI1015472A2 (enExample)
CA (1) CA2758187C (enExample)
ES (1) ES2505243T3 (enExample)
IL (1) IL215584A (enExample)
NZ (1) NZ595630A (enExample)
WO (1) WO2010118282A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2758271C (en) * 2009-04-09 2018-06-05 Robert Boyd Methods for preventing and/or treating lysosomal storage disorders
RU2015147509A (ru) 2009-10-19 2019-01-14 Амикус Терапьютикс, Инк. Новые композиции для предупреждения и/или лечения дегенеративных расстройств центральной нервной системы
EP2490533B1 (en) * 2009-10-19 2015-09-16 Amicus Therapeutics, Inc. Novel compositions for preventing and/or treating lysosomal storage disorders
EP3521451A1 (en) 2010-11-17 2019-08-07 Ionis Pharmaceuticals, Inc. Modulation of alpha synuclein expression
WO2013070981A2 (en) * 2011-11-08 2013-05-16 University Of Central Florida Research Foundation, Inc. Treating er stress related disorders by stabilizing intracellular calcium homeostasis
US9155695B2 (en) 2013-03-14 2015-10-13 Medtronic, Inc. Injectable ropinirole compositions and methods for making and using same
EP3087056A4 (en) 2013-12-23 2017-07-19 Alectos Therapeutics Inc. Glucocerebrosidase modulators and uses thereof
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
US10300155B2 (en) 2015-12-31 2019-05-28 Washington University Alpha-synuclein ligands
MX2019002673A (es) * 2016-09-12 2019-07-04 Hoffman Steven Composiciones y metodos para tratar demencia.
JP7217229B2 (ja) * 2016-11-15 2023-02-02 ハー・ルンドベック・アクチエゼルスカベット シヌクレイノパチーの治療のための薬剤、使用および方法
WO2019140231A1 (en) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Antisense oligonucleotides targeting alpha-synuclein and uses thereof
AU2019208011B2 (en) 2018-01-12 2025-06-05 Bristol-Myers Squibb Company Antisense oligonucleotides targeting alpha-synuclein and uses thereof
CN119606967B (zh) * 2024-12-13 2025-09-05 合肥工业大学 氯雷他定在制备用于预防和治疗血管钙化药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE243196T1 (de) * 1994-03-09 2003-07-15 Novo Nordisk As Piperidine und pyrrolidine
AU2002306848A1 (en) * 2001-03-23 2002-10-08 Elan Pharmaceuticals, Inc. Methods of treating alzheimer's disease with piperidin derivates
US6770625B2 (en) * 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US6670625B1 (en) * 2002-06-18 2003-12-30 Ge Medical Systems Global Technology Company, Llc Method and apparatus for correcting multipole aberrations of an electron beam in an EBT scanner
EP1558245A2 (en) * 2002-10-28 2005-08-03 Novo Nordisk A/S Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
AU2006254796B2 (en) * 2005-06-08 2012-08-16 Amicus Therapeutics, Inc. Treatment of CNS disorders associated with mutations in genes encoding lysosomal enzymes
KR101402554B1 (ko) * 2006-06-23 2014-06-19 아미쿠스 세라퓨틱스, 인코포레이티드 β-글루코세레브로시다제의 활성 증진에 의한 신경계 장애 치료 방법
US20080009156A1 (en) 2006-07-10 2008-01-10 Malin Glen K System and method for bonding coaxial cable
CA2758271C (en) * 2009-04-09 2018-06-05 Robert Boyd Methods for preventing and/or treating lysosomal storage disorders

Also Published As

Publication number Publication date
CN102448306B (zh) 2014-07-02
JP5634498B2 (ja) 2014-12-03
WO2010118282A1 (en) 2010-10-14
CA2758187C (en) 2017-03-07
NZ595630A (en) 2013-04-26
CA2758187A1 (en) 2010-10-14
ES2505243T3 (es) 2014-10-09
EP2416655B1 (en) 2014-06-25
IL215584A0 (en) 2011-12-29
HK1168005A1 (zh) 2012-12-21
US20100261753A1 (en) 2010-10-14
AU2010233187A1 (en) 2011-11-03
CN102448306A (zh) 2012-05-09
BRPI1015472A2 (pt) 2015-11-24
EP2416655A1 (en) 2012-02-15
AU2010233187B2 (en) 2015-10-08
US8304429B2 (en) 2012-11-06
JP2012523430A (ja) 2012-10-04
EP2416655A4 (en) 2012-09-05

Similar Documents

Publication Publication Date Title
IL215584A (en) Use of 5- (fluoromethyl) piperidine-3,4-diol, 5- (chloromethyl) piperidine-3,4-diol for the preparation of a drug for the prevention and / or treatment of degenerative diseases of the central nervous system
IL208390A0 (en) Permeant delivery system and methods for use thereof
PL2379132T3 (pl) Układ i sposób infuzji leku
EP2451367A4 (en) DEVICES, SYSTEMS AND METHODS OF SKIN TREATMENT USED BY TIME-CONTROLLED RELEASED SUBSTANCES
ZA201005090B (en) Carbon aerogels, process for their preparation and their use
IL219107A0 (en) 2-amino--5,5-difluoro-5,6-dihydro-4h-oxazines as bace 1 and/or bace 2 inhibitors
EP2533747B8 (de) Vorrichtung zur behandlung eines patienten mit vibrations-, tast- und/oder thermoreizen
EP2115651A4 (en) SYSTEMS AND METHODS FOR ONLINE GAMES
PL2442814T3 (pl) Bifidobacteria do leczenia cukrzycy i pokrewnych chorób
EP2491524A4 (en) SYSTEM AND DEVICE FOR CONSOLIDATING SIM, PERSONAL TOKEN AND ASSOCIATED APPLICATIONS
IL225597A0 (en) Pharmaceutical preparation, methods of treatment and its uses
IL208336A (en) Pyridazinone derivatives, drugs containing them and their uses and process for preparation
PL2401263T3 (pl) Podstawione pochodne azotu, zawierająca pochodne kompozycja farmaceutyczna, i sposób leczenia choroby Parkinsona przy ich użyciu
IL215583A (en) Use of Medical Material 5- (Fluorine and Methyl) Pipridine-3,4-Diol, 5- (Chloromethyl) Pipridine-3,4-Diol for the preparation of a drug for the prevention and / or treatment of lysosomal storage disorders in patients at risk of disease or being diagnosed with these disorders
EP2450038A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIABETIC NEUROPATHY AND MANUFACTURING AND USE METHODS
EP2413837A4 (en) METHODS FOR TREATING MYOFASCIAL, MUSCLE AND / OR BACK PAIN
EP2127665A4 (en) MEDICAL PREPARATION BASED ON EXENATIDE AND DALARGINE FOR THE TREATMENT OF PANCREATIC DIABETES
IL182361A0 (en) Play system for children, including playmat and playpieces
IL214560A0 (en) Durable treatment with 4-aminopyridine in patients with demyelination
SI2266619T1 (sl) Farmacevtski sestavek na osnovi hepatoprotektorja in prebiotika, njegova izdelava in uporaba
ZA201201146B (en) Isocyanate-terminated prepolymer,the method for preparing the same and the use thereof
ZA201201011B (en) Process for preparing levosimendan and intermediates for use in the process
WO2010112589A3 (de) Schnittschablone aus keramik
GB0821501D0 (en) Method, composition, and device, for the treatment of enzymes and saccharides disorder
EP2106604A4 (en) IMPROVED OPTIONAL DEVICE AND SYSTEM

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees